Rhythm Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy Rating

TipRanks49minutes ago · Ratings

TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $65

Futu News00:31 · Ratings

Express News | RPT-Rhythm Pharmaceuticals: Plan to Initiate New Phase 2 Trial Exploring Setmelanotide in Prader-Willi Syndrome

BreakingsJan 10 20:25

Rhythm Reports Preliminary Unaudited Net Revenues From Global Sales Of IMCIVREE Of $42M For Q4, Up 26% Q/Q

BenzingaJan 10 20:23

Express News | Rhythm Pharmaceuticals Inc: Net Rev FY24 Expected to Be About $130 Mln

BreakingsJan 10 20:19

Express News | Rhythm Pharmaceuticals:On Track to Report Topline Data From Global Phase 3 Trial Evaluating Setmelanotide in Acquired Hypothalamic Obesity in H1 2025

BreakingsJan 10 20:19